Concepedia

Mingjun Rui

MR

Statistics

Publications

6

Citations

144

H-Index

6

Active since

2020

Affiliations

China Pharmaceutical University(Current)

Mingjun Rui is an author at China Pharmaceutical University specializing in cancer therapeutics, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

2020–2022

6

Publications

6

Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China

Mingjun Rui, Zhengyang Fei, Yingcheng Wang et al. · Journal of Medical Economics · 2022 · 38 citations · Full text

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Yingcheng Wang, Mingjun Rui, Xin‐Yuan Guan et al. · Frontiers in Medicine · 2021 · 24 citations · Full text

Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model

Mingjun Rui, Fenghao Shi, Ye Shang et al. · Advances in Therapy · 2020 · 23 citations

, , +6

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

Pingyu Chen, Xintian Wang, Shengwen Zhu et al. · Frontiers in Public Health · 2022 · 22 citations · Full text

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US

Yingcheng Wang, Mingjun Rui, Lan Yang et al. · Frontiers in Public Health · 2021 · 21 citations · Full text

1–5 of 6